JP2024515809A5 - - Google Patents
Info
- Publication number
- JP2024515809A5 JP2024515809A5 JP2023565986A JP2023565986A JP2024515809A5 JP 2024515809 A5 JP2024515809 A5 JP 2024515809A5 JP 2023565986 A JP2023565986 A JP 2023565986A JP 2023565986 A JP2023565986 A JP 2023565986A JP 2024515809 A5 JP2024515809 A5 JP 2024515809A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- pharmaceutical composition
- composition according
- immune checkpoint
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2021/029552 WO2022231580A1 (en) | 2021-04-28 | 2021-04-28 | Combination therapy by using akr1c3-activated compound with immune checkpoint inhibitor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024515809A JP2024515809A (ja) | 2024-04-10 |
| JP2024515809A5 true JP2024515809A5 (enExample) | 2024-04-30 |
| JP7875886B2 JP7875886B2 (ja) | 2026-06-18 |
Family
ID=83847212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023565986A Active JP7875886B2 (ja) | 2021-04-28 | 2021-04-28 | Ａｋｒ１ｃ３活性化化合物及び免疫チェックポイント阻害剤を含む医薬組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240216401A1 (enExample) |
| EP (1) | EP4329745A4 (enExample) |
| JP (1) | JP7875886B2 (enExample) |
| KR (1) | KR20240004519A (enExample) |
| CN (1) | CN117729917A (enExample) |
| AU (1) | AU2021443620A1 (enExample) |
| BR (1) | BR112023020922A2 (enExample) |
| CA (1) | CA3216896A1 (enExample) |
| IL (1) | IL307974A (enExample) |
| WO (1) | WO2022231580A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119744168A (zh) * | 2022-09-09 | 2025-04-01 | 深圳艾欣达伟医药科技有限公司 | Ast-3424联用治疗白血病及淋巴瘤 |
| EP4755396A1 (en) | 2023-07-28 | 2026-06-10 | Ascentawits Pharmaceuticals, Ltd. | Treatment of p53 gene mutation or defect negative cancer and tumor patients |
| CN121646469A (zh) | 2023-09-05 | 2026-03-10 | 深圳艾欣达伟医药科技有限公司 | Ast-3424治疗癌症、肿瘤的给药方案及制药用途 |
| CN121985960A (zh) | 2023-10-18 | 2026-05-05 | 深圳艾欣达伟医药科技有限公司 | 治疗p53基因突变阴性、kras基因突变阳性、brca突变阳性患者 |
| CN121049512A (zh) * | 2024-05-28 | 2025-12-02 | 深圳艾欣达伟医药科技有限公司 | Ast-3424治疗肝癌 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5922791B2 (ja) * | 2012-10-29 | 2016-05-24 | 京セラ株式会社 | 弾性表面波センサ |
| US20170165364A1 (en) * | 2014-02-21 | 2017-06-15 | Idac Theranostics, Inc. | Therapeutic agent for solid cancer |
| WO2016145092A1 (en) * | 2015-03-10 | 2016-09-15 | Threshold Pharmaceuticals, Inc. | Dna alkylating agents |
| KR101985778B1 (ko) * | 2015-11-16 | 2019-06-04 | 아센타위츠 파마슈티컬즈 리미티드 | (r)- 및 (s)-1-(3-(3-n,n-다이메틸아미노카보닐)페녹시-4-나이트로페닐)-1-에틸-n,n'-비스(에틸렌)포스포르아미데이트, 조성물 및 이의 사용 방법 및 제조 |
| EP3458091B1 (en) * | 2016-05-20 | 2021-11-17 | Eli Lilly and Company | Combination therapy with notch and pd-1 or pd-l1 inhibitors |
| TW201919644A (zh) * | 2017-09-29 | 2019-06-01 | 台灣浩鼎生技股份有限公司 | 治療血癌的方法 |
| CN118834240A (zh) * | 2019-05-13 | 2024-10-25 | 深圳艾欣达伟医药科技有限公司 | 含氟化合物及抗癌医药用途 |
| EP4003314B1 (en) * | 2019-07-26 | 2024-07-10 | Espervita Therapeutics, Inc. | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease |
-
2021
- 2021-04-28 CA CA3216896A patent/CA3216896A1/en active Pending
- 2021-04-28 BR BR112023020922A patent/BR112023020922A2/pt unknown
- 2021-04-28 IL IL307974A patent/IL307974A/en unknown
- 2021-04-28 AU AU2021443620A patent/AU2021443620A1/en active Pending
- 2021-04-28 CN CN202180097625.2A patent/CN117729917A/zh active Pending
- 2021-04-28 EP EP21939529.0A patent/EP4329745A4/en active Pending
- 2021-04-28 WO PCT/US2021/029552 patent/WO2022231580A1/en not_active Ceased
- 2021-04-28 US US18/288,215 patent/US20240216401A1/en active Pending
- 2021-04-28 KR KR1020237039268A patent/KR20240004519A/ko active Pending
- 2021-04-28 JP JP2023565986A patent/JP7875886B2/ja active Active